Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy

Medullary thyroid cancer (MTC) is a rare malignancy that arises from calcitonin-producing C-cells. Curative treatment for patients with metastatic MTC is challenging. Identifying the mechanisms by which cancer cells inhibit the activity of immune cells provides an opportunity to develop new therapie...

Full description

Saved in:
Bibliographic Details
Published in:Genes 2021-09, Vol.12 (10), p.1534
Main Authors: Hińcza-Nowak, Kinga, Kowalik, Artur, Walczyk, Agnieszka, Pałyga, Iwona, Gąsior-Perczak, Danuta, Płusa, Agnieszka, Kopczyński, Janusz, Chrapek, Magdalena, Góźdź, Stanisław, Kowalska, Aldona
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antitumor activity
B7 Antigens - genetics
B7 Antigens - metabolism
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Calcitonin
Cancer therapies
Carcinoma, Neuroendocrine - drug therapy
Carcinoma, Neuroendocrine - genetics
Carcinoma, Neuroendocrine - immunology
Carcinoma, Neuroendocrine - pathology
Chemokines
Computational Biology - methods
Cytokines
Female
Gene expression
Humans
Immune system
Immunology
Immunotherapy
Immunotherapy - methods
Kinases
Ligands
Lymphatic system
Male
Malignancy
Medical prognosis
Metastases
Metastasis
Middle Aged
Monoclonal antibodies
Mutation
Patients
Statistical analysis
Thyroid cancer
Thyroid Neoplasms - drug therapy
Thyroid Neoplasms - genetics
Thyroid Neoplasms - immunology
Thyroid Neoplasms - pathology
Tumor Burden
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Medullary thyroid cancer (MTC) is a rare malignancy that arises from calcitonin-producing C-cells. Curative treatment for patients with metastatic MTC is challenging. Identifying the mechanisms by which cancer cells inhibit the activity of immune cells provides an opportunity to develop new therapies that restore anticancer activity. Little is known about the immunological phenomena underlying MTC. Here, we examined the expression profile of 395 genes associated with MTC. The study included 51 patients diagnosed with MTC at a single center. Bioinformatical analysis revealed that CD276 expression in MTC cells was at least three-fold higher than that in normal tissue. The expression of CD276 showed a weak but statistically significant positive correlation with tumor diameter, but we did not find a significant association between CD276 expression and other histopathological clinical factors, or the response to initial therapy. A search of published data identified the monoclonal antibody (inhibitor) enoblituzumab as a potential drug for patients diagnosed with MTC overexpressing CD276.
ISSN:2073-4425
2073-4425
DOI:10.3390/genes12101534